TL;DR
A 503B outsourcing facility supplying hospital systems needs products liability sized to the hospital purchase contract demand (typically $5M to $10M), dedicated recall coverage ($1M to $10M first-party), druggist professional liability, hospital additional-insured and GPO supplier endorsements, cGMP property and business interruption, and cyber/HIPAA. The program sits closer to a CDMO than a community pharmacy. We build it to satisfy the most demanding hospital schedule so a single program covers every customer.
503B Outsourcing Facilities · Texas
Texas hosts a top-3 US 503B outsourcing-facility cluster - Dallas-Fort Worth and Houston anchor the cluster. We help 503B operators navigate FDA registration COI requirements, cGMP-aligned property coverage, and hospital purchase contracts that demand $5M-$10M products with FDA-specific recall extensions.
The 503B environment is materially different from 503A patient-specific compounding. cGMP property exposures (validation losses, batch losses, cleanroom contamination) require manufacturer-classed forms; hospital procurement contracts require named-additional-insured plus 30-day notice; FDA-recall extensions on standard products forms are rarely sufficient at scale.
Problem 01 · cGMP property
Generic compounding-pharmacy property forms do not cover validation losses, large batch losses, or cleanroom contamination at meaningful limits. The 503B environment requires drug-manufacturer property forms with cGMP-aligned definitions and limits sized to actual batch values held on premises.
Cleanroom contamination claims - caused by HVAC failures, environmental excursions, or upstream utility events - can wipe out an entire batch, triggering both first-party property losses and downstream products and recall exposure. Coordination across property, products, and recall coverages matters more here than in any patient-specific compounding context.
Problem 02 · Hospital purchase contracts
Hospital procurement contracts with 503Bs typically require $5M-$10M products liability with the hospital named as additional insured, cGMP-aligned property coverage, FDA-recall extension, current FDA registration documentation, and primary/non-contributory wording. Vendor credentialing platforms enforce the schedule - gaps lock you out of purchase orders even after the supplier passes evaluation.
We help 503Bs review procurement insurance schedules from major hospital systems and IDNs before signing, flag terms that conflict with available carrier appetite, and rebuild programs to satisfy the schedule cleanly.
Problem 03 · Inspection history
FDA Form 483 observations, warning letters, and consent decree history all factor into underwriting. Recent enforcement actions can result in coverage being unavailable rather than just expensive - and renewal lead times stretch as carriers wait for closure documentation.
The cheapest underwriting position is a clean inspection history with closed-out observations. The most expensive position is an unaddressed warning letter at renewal time. Documentation discipline is the cheapest insurance investment a 503B can make.
Problem 01 · Hospital purchase contract compliance
Hospital purchase contracts and GPO supplier agreements (Vizient, Premier, HealthTrust) require products and completed operations at $5M-$10M, hospital additional-insured on a primary and non-contributory basis, waiver of subrogation, and 30-day notice of cancellation - all enforced through Symplr/Reptrax credentialing platforms.
Most 503Bs supplying multiple hospital systems discover that the union of all schedules is materially tougher than any single schedule. The program should be built to the toughest schedule so a single COI works across the entire customer base.
Problem 02 · Dedicated recall coverage
Hospital purchase contracts increasingly require dedicated recall coverage at $3M-$10M first-party, with the hospital and its affiliates named as additional insureds. The standard product is a stand-alone recall policy, not a sublimit on the products liability policy.
A real Class I recall of a sterile injectable product can drive $3M-$10M in execution costs (notification, retrieval, destruction, replacement manufacture, lost revenue during the recall window) plus regulatory penalties. A sublimit at $250K-$500K is structurally inadequate.
Problem 03 · cGMP property + validation
FDA cGMP inspection authority applies continuously to 503B outsourcing facilities under FD&C 503B. A property loss event that requires re-validation of the sterile core, BSCs, or environmental monitoring creates substantial recovery costs above standard property limits.
Property programs should include explicit validation loss extension and business interruption sized to hospital purchase contract revenue. Operators discovering this gap post-loss are typically 60-90 days into a stop-supply situation.
Problem 04 · AER reporting under 503B(b)(5)(B)
FD&C 503B(b)(5)(B) requires the outsourcing facility to report adverse events and product quality concerns to FDA within specified windows. The reporting trigger creates claim notification standards that some products policies do not align with by default.
Policy form alignment is mechanical to verify but commonly missed. AER-triggered claim notification should be explicit in the products liability policy, not left to default carrier language.
Carrier access
Generalist pharmacy carriers will write a 503B as a large compounding pharmacy. The placement looks fine on the COI. The placement fails at first hospital credentialing audit, when it turns out the recall coverage is a sublimit instead of dedicated or the validation extension is missing.
Our placements run through carriers with dedicated 503B underwriting and active appetite for sterile injectable compounders. We know which markets price the segment competitively vs which restrict appetite to <$10M revenue operators.
Programs anchored in Texas with broader placement across the major US life-sciences clusters - including the New Jersey pharma corridor and the North Carolina (RTP) cluster.
Pricing
Premium ranges for 503B outsourcing facilities at $5M-$50M revenue, the factors that drive cost, and sample programs by customer mix.
Frequently asked
503B operations are FDA-registered drug manufacturers under cGMP. The property exposure includes validation losses and large batch losses; products liability needs to scale with bulk distribution; and recall stakes are materially higher than patient-specific compounding.
$5M-$10M products liability with hospital named as additional insured, cGMP-aligned property coverage, FDA-recall extension, current FDA registration documentation, and primary/non-contributory wording.
A small number of specialty carriers and London-market layers write the 503B exposure with the right form. Generic compounding-pharmacy carriers will often decline.
Materially. Form 483 observations, warning letters, and consent decree history all factor into underwriting. Recent enforcement actions can result in coverage being unavailable rather than just expensive.
Dallas-Fort Worth and Houston are home to a top-tier US 503B cluster. Local insurance specialists understand the regional regulatory environment and supplier relationships.
Next steps
Five 503B coverage strategies by customer mix - hospital purchase contract anchored, GPO supplier, multi-customer distributed.
OpenFive recall coverage structures ranked by hospital purchase contract fit. First-party dedicated, products sublimit, captive-supported.
OpenFive questions about your operation. Get a single named coverage gap most likely to surface at first claim.
OpenPaste 3 hospital purchase contract indemnity clauses. Get a verdict on the risk transfer architecture.
OpenAuthoritative references
FDA registry of 503B outsourcing facilities under FD&C Act section 503B.
cGMP guidance for 503B outsourcing - the inspection standard FDA uses on routine visits.
503B sterile compounding follows USP 797 for environmental controls and BUD assignment.
Defines the commercial scope of 503B drug categories eligible for outsourcing supply.
AER obligations under FD&C 503B(b)(5)(B) - claim notification trigger for products policies.
Why operators choose this practice
Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.
Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.
Coverage review requests come back the same business day. MSA reads are typically half an hour or less.
Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.
Related deep-dives
Free coverage review
No marketing sequences, no list rental. Half-hour MSA reads are the standard.